Research map: Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study

Back to the article

Papers in this map

  1. Epidemiology of metabolic dysfunction-associated steatotic liver disease · Zobair M. Younossi · 2024 · 876 citations · Cited by this paper
  2. Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine · 2026 · Related
  3. A global federated real-world data and analytics platform for research · Matvey B. Palchuk · 2023 · 829 citations · Cited by this paper
  4. Letter: External Validation of Hepcidin Thresholds for Predicting Response to Iron Therapy in Active Inflammatory Bowel Disease · 2026 · Related
  5. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention · Philip M. Urban · 2019 · 828 citations · Cited by this paper
  6. Development and Validation of a Machine Learning Model to Prognosticate Hepatocellular Carcinoma · 2026 · Related
  7. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk · Philip M. Urban · 2019 · 621 citations · Cited by this paper
  8. Natural History of Recurrent Acute Pancreatitis: Implications for Interventional Trial Design · 2026 · Related
  9. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines · Sunil V. Rao · 2025 · 588 citations · Cited by this paper
  10. Letter: Low FODMAP Therapy in Paediatric Irritable Bowel Syndrome: Balancing Efficacy, Expectancy and Safety · 2026 · Related
  11. Cirrhotic Cardiomyopathy · Enrico Maria Zardi · 2010 · 365 citations · Cited by this paper
  12. Letter: Does the Association Between Mild Endoscopic Activity and Adverse Outcomes Justify Treatment Escalation in Older Adults With Inflammatory Bowel Disease? · 2026 · Related
  13. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study · Joon Ho Moon · 2023 · 175 citations · Cited by this paper
  14. Eosinophilic Oesophagitis Beyond the Oesophagus: High Prevalence of Chronic Rhinosinusitis‐Type Symptoms and Their Impact on Symptom Severity in Swiss EoE Cohort Study Patients · 2026 · Related
  15. Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions · Pranab M. Barman · 2020 · 84 citations · Cited by this paper
  16. Non‐Selective Beta‐Blocker Use Is Associated With Lower Mortality After Decompensation in Cirrhosis: A Nationwide Target Trial Emulation · 2026 · Related
  17. Global burden of liver cirrhosis 1990–2019 and 20 years forecast: results from the global burden of disease study 2019 · Yikai Wang · 2024 · 71 citations · Cited by this paper
  18. Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction‐Associated Steatohepatitis—Reanalysis of Fibrosis Stage 2–3 Subset · 2026 · Related
  19. Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention · Hirotoshi Watanabe · 2023 · 69 citations · Cited by this paper
  20. A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection · 2026 · Related
  21. CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates · Rayan Jo Rachwan · 2021 · 62 citations · Cited by this paper
  22. Patients with cirrhosis who have coronary artery disease treated with cardiac stents have high rates of gastrointestinal bleeding, but no increased mortality · Timothy S. Krill · 2017 · 53 citations · Cited by this paper
  23. Cause-specific mortality in patients with steatotic liver disease in the United States · Pedro Ochoa‐Allemant · 2025 · 47 citations · Cited by this paper
  24. Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease · Hannes Hagström · 2024 · 40 citations · Cited by this paper
  25. Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis · Agostino Di Ciaula · 2022 · 38 citations · Cited by this paper
  26. A Meta‐Analysis and Systematic Review on the Global Prevalence, Risk Factors, and Outcomes of Coronary Artery Disease in Liver Transplantation Recipients · Jieling Xiao · 2021 · 34 citations · Cited by this paper
  27. Cause-specific mortality among patients with cirrhosis in a population-based cohort study in Ontario (2000–2017) · Peter L. Wang · 2023 · 32 citations · Cited by this paper
  28. The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients · Natasa Paklar · 2023 · 32 citations · Cited by this paper
  29. Increasing prevalence of cirrhosis among insured adults in the United States, 2012–2018 · Daniela P. Ladner · 2024 · 27 citations · Cited by this paper
  30. Metabolic Dysfunction–Associated Steatotic Liver Disease—The New Epidemic of Chronic Liver Disease · Pere Ginès · 2025 · 27 citations · Cited by this paper
  31. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent · Pil‐Ki Min · 2024 · 26 citations · Cited by this paper
  32. Impact Of Cirrhosis On 90-Day Outcomes After Percutaneous Coronary Intervention (from A Nationwide Database) · Daniel Y. Lu · 2020 · 25 citations · Cited by this paper
  33. Meta‐analysis: Prevalence and impact of alcohol abstinence in alcohol‐associated cirrhosis · Wen Hui Lim · 2024 · 23 citations · Cited by this paper
  34. Efficacy and safety of concomitant use of proton pump inhibitors with aspirin-clopidogrel dual antiplatelet therapy in coronary heart disease: A systematic review and meta-analysis · Xiaofeng Luo · 2023 · 20 citations · Cited by this paper
  35. Shorter Dual Antiplatelet Therapy for Older Adults After Percutaneous Coronary Intervention · Dae Yong Park · 2024 · 19 citations · Cited by this paper
  36. Temporal trends in the utilization and outcomes of percutaneous coronary interventions in patients with liver cirrhosis · Fahad Alqahtani · 2019 · 18 citations · Cited by this paper
  37. Global burden of metabolic dysfunction-associated steatotic liver disease from 1990 to 2021 and the prediction for the next 10 years · Zhuang Lin · 2025 · 18 citations · Cited by this paper
  38. Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review · Attia Mustafa · 2025 · 17 citations · Cited by this paper
  39. Incidence of Major Cardiovascular Events in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease in the General Population · Yvonne Huber · 2025 · 15 citations · Cited by this paper

Source: OpenAlex (CC0)